Non-invasive ventilation nursing: BiPAP, CPAP, and NIV management

Non-invasive ventilation (NIV) delivers positive-pressure respiratory support through a mask interface rather than an endotracheal tube. It is one of the most impactful interventions in acute care: a well-timed trial of NIV can prevent intubation, reduce ICU length of stay, and lower mortality in select patient populations. For nursing students and new graduates, mastering NIV means understanding the difference between BiPAP and CPAP, knowing exactly who benefits from each mode, recognizing the early signs of NIV failure, and providing the hands-on care — mask fit, skin protection, patient coaching — that determines whether a trial succeeds or fails.

This guide covers the full clinical picture: indications, contraindications, interface selection, pressure settings, nursing monitoring, failure criteria, and NCLEX-specific traps. For patients who progress beyond NIV, see the mechanical ventilation nursing guide. For background on oxygen delivery systems, see the oxygen therapy nursing guide. ABG interpretation is covered in detail in the ABG interpretation guide.

Quick reference	Detail
NIV definition	Positive-pressure ventilatory support delivered via mask (no endotracheal tube)
Two main modes	BiPAP (bilevel positive airway pressure) and CPAP (continuous positive airway pressure)
BiPAP pressures	IPAP 8–20 cmH2O (inspiratory), EPAP 4–8 cmH2O (expiratory)
CPAP pressure	5–15 cmH2O (single continuous pressure)
SpO2 target	≥ 90% (≥ 88% in chronic hypercapnic COPD to avoid hypercapnic drive suppression)
RR target	< 25 breaths/min within 1–2 hours of NIV initiation
Most common interface	Full face (oronasal) mask — covers nose and mouth
Contraindication — absolute	Inability to protect airway (absent gag, respiratory arrest)
NIV failure timeframe	Reassess at 1–2 hours; failure = worsening ABGs, rising RR, declining mental status

BiPAP vs CPAP: the core distinction

BiPAP and CPAP are both forms of NIV but they work through different mechanisms and treat different problems. Confusing the two is a common source of NCLEX errors.

CPAP delivers one fixed pressure throughout the entire respiratory cycle — both during inhalation and exhalation. It does not assist the patient’s inspiratory effort; it simply maintains a constant pneumatic splint that keeps the airway open and recruits collapsed alveoli. The pressure keeps alveoli from closing at end-expiration, improving oxygenation and reducing the work of breathing against a collapsed airway. CPAP is the preferred modality for obstructive sleep apnea (OSA) and cardiogenic pulmonary edema.

BiPAP delivers two distinct pressures: a higher inspiratory positive airway pressure (IPAP) triggered when the patient begins to inhale, and a lower expiratory positive airway pressure (EPAP) that remains during exhalation. The IPAP actively augments each breath, increasing tidal volume and allowing CO2 elimination. The EPAP functions the same as PEEP in mechanical ventilation — it keeps alveoli open between breaths. BiPAP is the preferred modality for hypercapnic (Type II) respiratory failure, where the patient needs help with ventilation, not just oxygenation.

The pressure support delivered is the difference between IPAP and EPAP — typically 4–10 cmH2O. A BiPAP set at IPAP 14 / EPAP 6 delivers 8 cmH2O of pressure support per breath.

Feature	CPAP	BiPAP
Pressures	Single continuous pressure (5–15 cmH2O)	Two pressures: IPAP (8–20) + EPAP (4–8 cmH2O)
Mechanism	Pneumatic splint — holds airway open, recruits alveoli; does not augment breaths	Actively augments each inspiration; EPAP maintains alveolar recruitment
CO2 elimination	Minimal — no augmentation of tidal volume	Yes — increased tidal volume promotes CO2 washout
Primary indications	OSA, cardiogenic pulmonary edema, mild hypoxemia	COPD exacerbation, OHS, hypercapnic respiratory failure, immunocompromised with hypoxemia
Preferred for Type II failure	No	Yes — BiPAP corrects hypercapnia by increasing ventilation
Preferred for cardiogenic edema	Yes — reduces preload and afterload; first-line per many guidelines	Second-line — some benefit but less evidence than CPAP
Patient effort required	Patient must initiate all breaths at full effort	Machine assists each breath — less respiratory muscle work
Backup rate	Not applicable	Can set a minimum backup RR for apnea protection

Indications for NIV

COPD exacerbation (hypercapnic respiratory failure)

This is the best-evidenced indication for BiPAP. Patients with acute COPD exacerbation develop Type II respiratory failure — pH falls, PaCO2 rises, and they tire rapidly from increased work of breathing against dynamic hyperinflation. BiPAP augments each breath, reduces respiratory muscle fatigue, and corrects respiratory acidosis. Randomized controlled trials show BiPAP reduces the intubation rate, ICU mortality, and hospital length of stay compared with standard medical therapy alone. See the COPD nursing guide for the full exacerbation management picture and the acute respiratory failure guide for Type I vs Type II classification.

Cardiogenic pulmonary edema

Flash pulmonary edema from acute decompensated heart failure floods the alveoli, causing severe hypoxemia. CPAP at 5–10 cmH2O is the first-line NIV modality: positive pressure drives fluid from the alveoli back into the vasculature, reduces venous return (preload), lowers left ventricular wall stress (afterload), and improves oxygenation rapidly — often within 30–60 minutes. Evidence supports a reduction in intubation rates. BiPAP is a reasonable alternative but many guidelines prefer CPAP as first-line for cardiogenic edema specifically. For the full heart failure picture see the heart failure nursing guide.

Obstructive sleep apnea

CPAP is the definitive therapy for OSA. It maintains upper airway patency throughout sleep, preventing the repetitive apneic episodes that fragment sleep and cause nocitutional hypoxemia. Nursing students encounter home CPAP patients in acute care settings; these patients should use their own CPAP equipment when hospitalized and it should be documented on the medication administration record.

Immunocompromised patients with hypoxemia

Patients who are immunocompromised — from hematologic malignancy, solid organ transplant, or high-dose corticosteroids — face dramatically higher infection risk with endotracheal intubation, particularly ventilator-associated pneumonia (VAP). A trial of NIV to avoid intubation is clinically important in this population. If NIV fails, intubation proceeds promptly; a delayed intubation after a failed NIV trial carries higher mortality than earlier intubation would have.

Obese hypoventilation syndrome (OHS)

OHS combines obesity (BMI > 30) with daytime hypercapnia (PaCO2 > 45 mmHg) not attributable to another cause. Patients typically present with somnolence, polycythemia, and right heart strain. BiPAP addresses both components — the hypoxemia via EPAP and the hypoventilation via IPAP-driven tidal volume augmentation.

Contraindications to NIV

Contraindication	Reasoning
Inability to protect airway	Absent gag reflex, altered mental status, or unconsciousness → aspiration risk with mask; NIV cannot protect the airway. Intubation required.
Respiratory arrest / apnea	NIV requires the patient to trigger breaths (or at minimum tolerate the mask). Apnea demands intubation immediately.
Hemodynamic instability	Positive pressure reduces venous return. In cardiogenic shock or severe hypotension, NIV may worsen cardiac output. Stabilize hemodynamics first.
Active vomiting or upper GI hemorrhage	High aspiration risk. Positive pressure mask traps vomitus at the airway. Secure the airway with ETT first.
Inability to cooperate	Patient must tolerate the mask and not remove it repeatedly. Severe agitation or delirium prevents effective NIV and delays definitive treatment.
Copious unmanageable secretions	NIV cannot facilitate aggressive suctioning. Thick secretions that block the airway require intubation for airway clearance.
Facial trauma or recent facial/upper airway surgery	Mask placement is impossible or contraindicated. Alternative interfaces (helmet NIV) may be used in specialist centers.
Undrained pneumothorax	Positive pressure can rapidly expand a pneumothorax into tension pneumothorax. Chest tube must be placed before starting NIV.
Fixed upper airway obstruction	A structural obstruction (tumor, epiglottitis with complete obstruction) cannot be bypassed by a mask — intubation or surgical airway required.

Interface selection

The mask interface determines patient comfort, leak management, and ultimately the success of a NIV trial. Match the interface to the clinical situation and the patient’s anatomy.

Full face (oronasal) mask — covers both nose and mouth. The standard interface for acute care NIV. Prevents air leak through the mouth, tolerates higher pressures, and is the most practical choice when patients are mouth-breathing from dyspnea. The primary disadvantage is claustrophobia and the inability to eat, drink, or speak with the mask on. This is the interface you will see in most hospital acute NIV trials.

Nasal mask — covers the nose only. Widely used for chronic home NIV (COPD, OHS, OSA). Lower claustrophobia burden and allows speech. Problematic in acute care because severely dyspneic patients mouth-breathe, causing large air leaks that defeat the pressure delivery.

Nasal pillows — soft cushions that seal at the nares. Preferred by many home OSA patients for comfort. Not suitable for high-pressure acute NIV; leaks become problematic above ~12 cmH2O.

Total face mask — a clear helmet-like shield that seals around the entire face. Useful when a standard full face mask cannot achieve an adequate seal (facial hair, unusual anatomy) or when a patient is claustrophobic with oronasal masks. Pressure delivery is effective but communication and assessment are more limited.

Helmet NIV — a cylinder that encases the entire head. Predominantly research and specialist setting. Delivers uniform pressure with less facial skin contact; increasingly studied for ARDS management.

Typical pressure settings and titration

Initial settings are based on the clinical indication. The goal is the minimum pressure that achieves the therapeutic target — unnecessary pressure increases patient discomfort and leak.

CPAP starting settings: Begin at 5–8 cmH2O. Titrate upward by 2 cmH2O increments to maintain SpO2 at target (≥ 90%) and reduce work of breathing. Maximum effective range is approximately 10–15 cmH2O. For cardiogenic pulmonary edema, 5–10 cmH2O is typical.

BiPAP starting settings: A common starting point is IPAP 10 / EPAP 4 cmH2O. Titrate IPAP upward in 2 cmH2O increments to improve tidal volume, reduce RR, and correct hypercapnia (rising pH, falling PaCO2 on ABG). Maintain a minimum gap of 4 cmH2O between IPAP and EPAP. Maximum IPAP is typically 20 cmH2O before considering intubation. The backup rate (typically 10–12 breaths/min) provides a minimum breath delivery if the patient becomes apneic.

Monitoring targets after initiation:

SpO2 ≥ 90% (or per individualized target — some COPD patients have a lower target to avoid suppressing hypoxic drive)
RR < 25 breaths/min within 1–2 hours
pH improving toward ≥ 7.35 on ABG
PaCO2 trending down (in hypercapnic patients)
Patient comfort and cooperation
Reduced use of accessory muscles

Adjust FiO2 on the NIV circuit (or titrate supplemental oxygen blended into the circuit) independently of pressure settings. Do not raise pressure settings to improve oxygenation when the issue is FiO2 — these are separate dials.

Nursing monitoring during NIV

Parameter	Normal / target range	Action threshold
SpO2	≥ 90% (≥ 88% in chronic hypercapnic COPD)	SpO2 < 88% → increase FiO2, reassess mask seal; if persistent → escalate
Respiratory rate	< 25 breaths/min at 1–2 hours	RR > 30 and rising → NIV failing; escalate to provider
Work of breathing	Accessory muscle use decreasing; patient less distressed	No improvement or worsening WOB at 1 hour → failure sign
ABG: pH	7.35–7.45	pH < 7.25 on NIV (especially if not improving) → intubation discussion
ABG: PaCO2	35–45 mmHg (or chronic baseline for COPD patients)	Rising PaCO2 with worsening pH → ventilation is inadequate; escalate
ABG: PaO2	60–100 mmHg (55–80 mmHg acceptable in ARDS/COPD)	PaO2 < 55 despite FiO2 adjustment → escalate
Heart rate and blood pressure	HR 60–100; BP at patient's baseline	Hypotension → positive pressure may be reducing venous return; reassess NIV suitability
Mental status	Alert and cooperative enough to tolerate mask	Declining GCS or agitation → airway protection concern; consider intubation
Mask seal / leak	Visible leak at device display ≤ 20–24 L/min (device-dependent)	Large audible leak + high leak display reading → refit mask, adjust headgear
Skin condition (nasal bridge)	Intact, no erythema or breakdown	Redness, blistering → apply foam barrier dressing; consider interface change

Check and document all parameters every 30–60 minutes during the first few hours of NIV initiation. Once stable, monitoring frequency can extend based on unit protocol and patient acuity.

NIV failure: recognition and escalation

The first 1–2 hours of NIV are the critical window. If the patient is responding, you will see measurable improvement: SpO2 rising, RR falling, accessory muscle use decreasing, patient looking less distressed, and ABGs improving. Absence of these signs — or deterioration — defines NIV failure.

NIV failure criterion	Clinical significance	Action
Worsening or no improvement in ABGs at 1–2 hours	Ventilatory support is inadequate; gas exchange not improving despite NIV	Notify provider immediately; prepare for intubation
pH < 7.25 and not improving	Severe acidosis threshold; risk of cardiac arrhythmia and arrest	Emergent provider notification; intubation likely
Rising RR (> 30–35) with increased WOB	Patient fatiguing; respiratory muscles failing faster than NIV can compensate	Escalate; delay worsens outcome
Declining mental status / GCS	Loss of airway protection; cannot cooperate with mask; aspiration risk	Intubation; remove mask immediately if consciousness drops acutely
Hemodynamic deterioration	Positive pressure reducing venous return in a compromised cardiovascular system	Halt NIV; resuscitate; reassess etiology
Inability to tolerate mask	Patient repeatedly removing mask; insufficient duration of NIV delivered	Attempt interface change, anxiolytic if appropriate; if persistent — decision re: intubation or palliative goals
SpO2 < 88% despite maximum FiO2	NIV cannot deliver sufficient oxygen; shunt physiology not responsive to pressure alone (as in severe ARDS)	Escalate; ARDS typically requires intubation — see ARDS nursing guide

A failed NIV trial does not mean NIV was wrong to try. A 1–2 hour trial with clear escalation criteria is the standard approach. The risk lies in recognizing failure late — do not wait until the patient is in extremis before calling the provider.

Skin breakdown prevention

Pressure injury from the mask interface is common during extended NIV use. The nasal bridge is the highest-risk site because it bears the most mask contact force. Prevention is a nursing responsibility and should start before the first skin breakdown appears.

Prevention strategies:

Apply a thin foam barrier dressing (hydrocolloid or foam) to the nasal bridge before mask application and replace at each interface check
Inspect skin every 2–4 hours; document findings
Rotate between interface types when clinically possible (for example, alternating full face mask with nasal mask during periods of lower acuity or during brief breaks)
Apply moisture barrier cream to areas at risk for maceration from sweat and humidity
Ensure the mask is as loose as possible while still maintaining an adequate seal — overtightening accelerates skin breakdown without improving seal significantly
Ensure the humidifier is functioning; dry pressurized gas causes mucosal drying and nasal discomfort that leads to non-compliance

Patient education and comfort management

A cooperative patient is the most important determinant of NIV success outside of the clinical indication itself. Patients who understand what the mask will feel like and why it is helping are significantly more likely to tolerate it.

Before mask application:

Explain the purpose in plain language: “This mask will help you breathe with less effort and give you more oxygen without needing a breathing tube.”
Describe the sensation: “It will feel like air pushing in when you breathe in. It may feel strange at first but most people get used to it within a few minutes.”
Show the patient the mask before applying it

During NIV:

Stay with the patient during the first 10–15 minutes of initiation — this is when tolerance is established or abandoned
Give clear, calm verbal coaching: “Breathe with the machine. Let it help you. Don’t fight it.”
If the patient is claustrophobic, holding the mask loosely against their face (not strapped) for the first minute or two can reduce panic before the headgear is secured
Administer anxiolytics if ordered and if respiratory status permits (low-dose lorazepam or midazolam is occasionally used; caution is required because sedation impairs respiratory drive and cooperation)
Address pain, if present — pain from rib fractures or abdominal distension reduces cooperation dramatically

Breaks from NIV:

Oral hygiene, eating (if tolerated), and brief communication breaks are permitted in stable patients
Document the duration of each break — total NIV hours per shift matters clinically
During breaks, provide appropriate supplemental oxygen via face mask or nasal cannula

NCLEX tips: non-invasive ventilation

BiPAP delivers two pressures; CPAP delivers one. IPAP assists inspiration; EPAP maintains airway patency. CPAP has no inspiratory assist — it is a single fixed pressure.
BiPAP is first-line for COPD exacerbation with hypercapnia. The evidence is robust: BiPAP reduces intubation rates and mortality in Type II respiratory failure.
CPAP is preferred for cardiogenic pulmonary edema, not BiPAP — positive pressure reduces preload and afterload, rapidly improving oxygenation. CPAP is the first-line NIV modality per most guidelines for this indication.
NIV does NOT replace intubation in respiratory arrest. A patient who is apneic or in respiratory arrest requires immediate bag-mask ventilation and emergent intubation. NIV requires the patient to be breathing.
BiPAP is contraindicated in patients who cannot protect their airway. No gag reflex, significantly altered mental status, or inability to cooperate are contraindications. Aspiration risk with a mask is unacceptably high.
The IPAP/EPAP pressure difference = pressure support. IPAP 14 / EPAP 6 delivers 8 cmH2O of pressure support. This is what augments tidal volume and drives CO2 elimination.
Nasal bridge skin breakdown is the most common NIV complication. Foam dressings should be applied prophylactically, not reactively.
An ABG at 1–2 hours is the key NIV failure assessment tool. Clinical improvement alone is not sufficient — pH and PaCO2 must be trending in the right direction.
Humidification matters. Dry pressurized gas causes mucosal drying, discomfort, and non-compliance. The humidifier should always be functioning during NIV.
CPAP at 5–10 cmH2O for cardiogenic edema; BiPAP IPAP 8–20 / EPAP 4–8 for COPD. Know the typical ranges for NCLEX — you may be asked to identify an appropriate initial setting.
Rising RR + worsening WOB + no ABG improvement = NIV failure. This combination at 1–2 hours means you must escalate immediately.
Immunocompromised patients benefit from NIV because intubation carries VAP risk. Avoiding intubation in this population, when possible, reduces hospital-acquired infection.
Full face mask is the standard acute care interface — covers nose and mouth, prevents leak during mouth-breathing, tolerates higher pressures.
Undrained pneumothorax is a contraindication to NIV. Positive pressure can convert a simple pneumothorax into a life-threatening tension pneumothorax.
For COPD patients, target SpO2 88–92%, not 94–98%. Excessive oxygen in chronic hypercapnic COPD can suppress the hypoxic drive and worsen CO2 retention. This is an NCLEX-tested distinction.
An ARDS patient typically requires intubation, not NIV alone. NIV failure rates are high in ARDS because the degree of shunt physiology does not respond sufficiently to non-invasive pressure delivery. See the ARDS nursing guide for lung-protective ventilation strategy.
The backup rate on BiPAP protects against apnea. If the patient stops triggering breaths, the machine delivers the backup rate. This is a safety feature, not a routine setting.
Declining mental status during NIV is an escalation trigger, not a reason to try a higher pressure. If GCS is dropping, airway protection is the clinical priority — call the provider.

Putting it together

NIV works when the right patient gets the right modality at the right time. COPD exacerbation with a pH of 7.28 and rising PaCO2 on a BiPAP trial has decades of evidence behind it. Flash pulmonary edema turning around within 45 minutes of CPAP initiation is one of the most satisfying acute interventions in medicine. The nurse’s role is not only to apply the equipment but to assess whether it is working, keep the patient comfortable and cooperative enough to sustain the trial, protect the skin, and recognize early enough when the patient is failing so that escalation to mechanical ventilation happens before the patient deteriorates further.

Use the ABG interpretation guide to interpret serial blood gases during NIV trials and understand whether respiratory acidosis is correcting. For the classification of Type I vs Type II respiratory failure that determines which NIV modality is appropriate, see the acute respiratory failure guide.

Written by Lindsay Smith, AGPCNP. Reviewed for clinical accuracy and NCLEX alignment.